SG11201811580SA - Compositions, devices, and methods for the treatment of alcohol use disorder - Google Patents

Compositions, devices, and methods for the treatment of alcohol use disorder

Info

Publication number
SG11201811580SA
SG11201811580SA SG11201811580SA SG11201811580SA SG11201811580SA SG 11201811580S A SG11201811580S A SG 11201811580SA SG 11201811580S A SG11201811580S A SG 11201811580SA SG 11201811580S A SG11201811580S A SG 11201811580SA SG 11201811580S A SG11201811580S A SG 11201811580SA
Authority
SG
Singapore
Prior art keywords
international
pct
floor
methods
alcohol use
Prior art date
Application number
SG11201811580SA
Other languages
English (en)
Inventor
Roger Crystal
Arvind Agrawal
Edward T Maggio
Original Assignee
Opiant Pharmaceuticals Inc
Aegis Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opiant Pharmaceuticals Inc, Aegis Therapeutics Llc filed Critical Opiant Pharmaceuticals Inc
Publication of SG11201811580SA publication Critical patent/SG11201811580SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0065—Inhalators with dosage or measuring devices
    • A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/06—Inhaling appliances shaped like cigars, cigarettes or pipes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Mechanical Engineering (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SG11201811580SA 2016-06-24 2017-06-26 Compositions, devices, and methods for the treatment of alcohol use disorder SG11201811580SA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662354465P 2016-06-24 2016-06-24
US201662419736P 2016-11-09 2016-11-09
PCT/US2017/039300 WO2017223566A1 (en) 2016-06-24 2017-06-26 Compositions, devices, and methods for the treatment of alcohol use disorder

Publications (1)

Publication Number Publication Date
SG11201811580SA true SG11201811580SA (en) 2019-01-30

Family

ID=60784803

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10202013034QA SG10202013034QA (en) 2016-06-24 2017-06-26 Compositions, devices, and methods for the treatment of alcohol use disorder
SG11201811580SA SG11201811580SA (en) 2016-06-24 2017-06-26 Compositions, devices, and methods for the treatment of alcohol use disorder

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10202013034QA SG10202013034QA (en) 2016-06-24 2017-06-26 Compositions, devices, and methods for the treatment of alcohol use disorder

Country Status (12)

Country Link
US (1) US20190209464A1 (es)
EP (1) EP3474842A4 (es)
JP (2) JP2019520361A (es)
KR (2) KR102634829B1 (es)
CN (1) CN109789122A (es)
AU (2) AU2017281941A1 (es)
CA (1) CA3028731A1 (es)
MX (2) MX2018015985A (es)
PH (1) PH12018502738A1 (es)
RU (2) RU2022103366A (es)
SG (2) SG10202013034QA (es)
WO (1) WO2017223566A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017281941A1 (en) * 2016-06-24 2019-02-07 Aegis Therapeutics Llc Compositions, devices, and methods for the treatment of alcohol use disorder
CA3043028A1 (en) * 2016-11-09 2018-05-17 Opiant Pharmaceuticals, Inc. Compositions, devices, and methods for the treatment of opioid-receptor-mediated conditions
CA3044221A1 (en) * 2016-11-18 2018-05-24 Opiant Pharmaceuticals, Inc. Intranasal nalmefene compositions and methods for the treatment of opioid overdose
US20210220346A1 (en) * 2018-05-17 2021-07-22 Aegis Therapeutics Llc Formulations and methods for the prevention of opioid overdose
WO2020132263A1 (en) * 2018-12-20 2020-06-25 Aegis Therapeutics, Inc. Compositions, devices, and methods for the treatment of overdose and reward-based disorders
WO2020230676A1 (ja) * 2019-05-16 2020-11-19 株式会社新日本科学 経鼻投与用の粉末製剤及びその製造方法
US11278709B1 (en) 2021-03-12 2022-03-22 Pocket Naloxone Corp. Drug delivery device and methods for using same
WO2023147443A2 (en) * 2022-01-26 2023-08-03 Tulex Pharmaceuticals Inc. Novel compositions

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4882335A (en) * 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US5069895A (en) * 1989-11-09 1991-12-03 Diamond Ivan F Methods for the treatment of alcohol intoxication and dependence
EP0444778A1 (en) * 1990-02-14 1991-09-04 Alcon Laboratories, Inc. Use of alkyl saccharides to enhance the penetration of drugs
JP2005508888A (ja) * 2001-08-14 2005-04-07 バイオティ セラピーズ コーポレイション アルコール依存症またはアルコール中毒を治療する方法
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
US9895444B2 (en) * 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20070212307A1 (en) * 2006-02-10 2007-09-13 Daniel Wermeling Pharmaceutical Compositions Comprising an Opioid Receptor Antagonist and Methods of Using Same
CA2677205A1 (en) * 2007-01-31 2008-08-07 University Of Virginia Patent Foundation Topiramate plus naltrexone for the treatment of addictive disorders
CA2697990A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
JP5437236B2 (ja) * 2008-04-16 2014-03-12 一般財団法人化学及血清療法研究所 トロンビン固定化生体吸収性シート製剤の製造方法
ES2686299T3 (es) * 2010-10-29 2018-10-17 Troikaa Pharmaceuticals Ltd Composiciones nasales de vitamina B12
ME02958B (me) * 2011-05-13 2018-07-20 Euro Celtique Sa Intranazalni farmaceutski dozni oblici коji obuhvataju nalokson
US10485798B2 (en) * 2012-08-22 2019-11-26 Aptapharma Inc. Methylnaltrexone nasal formulations, methods of making, and use thereof
US20140171458A1 (en) * 2012-12-13 2014-06-19 3B Pharmaceuticals, Inc. Intranasal naltrexone
DE202013105715U1 (de) * 2013-08-22 2014-02-19 Sipnose Ltd. Vorrichtung zur Abgabe einer vorbestimmten Menge einer Substanz an eine natürliche Öffnung des Körpers
EP3082817A4 (en) 2013-12-18 2017-06-21 Aegis Therapeutics, LLC Compositions for drug administration
US9480644B2 (en) * 2014-03-14 2016-11-01 Opiant Pharmaceuticals, Inc. Nasal drug products and methods of their use
AU2017281941A1 (en) 2016-06-24 2019-02-07 Aegis Therapeutics Llc Compositions, devices, and methods for the treatment of alcohol use disorder

Also Published As

Publication number Publication date
RU2767062C2 (ru) 2022-03-16
US20190209464A1 (en) 2019-07-11
MX2022013671A (es) 2022-12-13
WO2017223566A1 (en) 2017-12-28
CA3028731A1 (en) 2017-12-28
EP3474842A4 (en) 2020-01-29
JP2019520361A (ja) 2019-07-18
AU2023202420A1 (en) 2023-05-11
KR20220167279A (ko) 2022-12-20
PH12018502738A1 (en) 2019-10-21
RU2019101810A (ru) 2020-07-27
AU2017281941A1 (en) 2019-02-07
KR102634829B1 (ko) 2024-02-07
SG10202013034QA (en) 2021-02-25
RU2019101810A3 (es) 2020-10-14
KR102453781B1 (ko) 2022-10-12
KR20190055057A (ko) 2019-05-22
CN109789122A (zh) 2019-05-21
EP3474842A1 (en) 2019-05-01
RU2022103366A (ru) 2022-03-01
MX2018015985A (es) 2019-09-13
JP2022088592A (ja) 2022-06-14
JP7492548B2 (ja) 2024-05-29

Similar Documents

Publication Publication Date Title
SG11201811580SA (en) Compositions, devices, and methods for the treatment of alcohol use disorder
SG11201908330PA (en) Farnesoid x receptor agonists and uses thereof
SG11201906412SA (en) Pyridine compounds as allosteric shp2 inhibitors
SG11201808990QA (en) Compositions for topical application of compounds
SG11201408174UA (en) Antibody formulation
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201407397WA (en) Formulations and methods for vaginal delivery of antiprogestins
SG11201908512YA (en) Somatostatin modulators and uses thereof
SG11201408261UA (en) Syringe
SG11201408318RA (en) Compositions and methods for transmucosal absorption
SG11201805570WA (en) Systems and methods for long term transdermal administration
SG11201811237WA (en) Combination therapies
SG11201900349VA (en) Somatostatin modulators and uses thereof
SG11201808270PA (en) Substituted indoline derivatives as dengue viral replication inhibitors
SG11201811230RA (en) Compositions and methods for reducing ocular neovascularization
SG11201808237UA (en) Substituted indole compound derivatives as dengue viral replication inhibitors
SG11201809908TA (en) Stabilized glycopeptide antibiotic formulations
SG11201900558RA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201808138YA (en) Substituted indole derivatives as dengue viral replication inhibitors
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201408240TA (en) Treatment of motor and movement disorder side effects associated with parkinson's disease treatments
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof
SG11201903312VA (en) Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
SG11201907196YA (en) Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201811209QA (en) Oral gastroretentive formulations and uses thereof